Description

Healthcare Financing - IPO, Venture, Private Equity, and M&A OutlookProgram Description

We are thrilled to return to an in-person event as we reconnect with colleagues and build new relationships.

Join us for our Annual Financing and M&A Outlook conference.

The Keynote speaker is Jeffrey Barlow, President of Canaccord Genuity LLC (US). Following Jeff’s remarks, we will discuss the latest financing trends and predictions for 2023. David Uffer will moderate and will be joined by a panel of multidisciplinary experts from Investment banking, Private Equity Funds, Corporate Venture, and Venture Capital. The panel includes Katherine Andersen, Head of SVB Life Science & Healthcare; Joshua Phillips, Founder & Managing Partner, CHV.

Audience comments and questions will be an essential part of the conversation.

Keynote Speaker

Jeffrey Barlow, President, Canaccord Genuity LLC (US)

Jeff joined the firm in February 2007 and successfully expanded the firm’s Life Sciences practice before becoming head of US Investment Banking in 2011. He has extensive experience advising clients in all aspects of financings, mergers, and acquisitions and has completed hundreds of transactions during his career.

Program Moderator

David Uffer, Vice President Commercial Development, MedTech, General Inception

David leads the Medtech portion of General Inception. The firm co-founds companies with innovators and entrepreneurs across all segments of the healthcare ecosystem. Before General Inception, he was a Partner at Alira Health and Director, Business Development & Licensing at Covidien.

Panelists

Katherine Andersen, Head of SVB Life Science & Healthcare, SPD Silicon Valley Bank

Katherine Andersen serves as head of US Life Science & Healthcare at Silicon Valley Bank, which includes management of our accelerator/growth, corporate banking, sponsor finance & institutional leveraged finance teams.

Joshua Phillips, Founder & Managing Partner, CHV

Mr. Phillips is a Founder and Managing Partner of CHV and has been a member of the Investment Committees of the general partners of CHV I and CHV II since 2008. He is actively involved in fund management, including investments and capital raising. He has led CHV I and CHV II investments in the medical device, women’s health, and molecular diagnostics markets.

Join this timely program to hear about the latest market trends and challenges from these industry leaders.

Who should attend?

C-level executives, board members, investors, and other senior leaders who want a better understanding of how to make important decisions at strategic inflection points for their company in 2023.

CLICK HERE TO REGISTER